11/4/2025

Iloprost Inhalation Solution (Ventavis)

Products Affected - Description

- Ventavis inhalation solution, Janssen, 10 mcg/mL, 1 mL ampule, 30 count, NDC 66215-0302-30
- Ventavis inhalation solution, Janssen, 20 mcg/mL, 1 mL ampule, 30 count, NDC 66215-0303-30

Reason for the Shortage

- Janssen does not have Ventavis available for use in the US for new patients due to the FDA-approved delivery system (I-neb AAD system) being discontinued by Philips Respironics. The 10 mcg/mL and 20 mcg/mL vials were both discontinued in late-September 2025.

Available Products

- There are no available products.

Estimated Resupply Dates

- Janssen discontinued Ventavis 10 mcg/mL 1 mL ampules and 20 mcg/mL 1 mL ampules in late-September 2025.

Implications for Patient Care

- Providers will need to work to switch patients to an alternative pulmonary hypertension treatment. New prior authorizations for alternative treatments will likely be required

Updated

Updated November 4, 2025 by Rachael Freeman, PharmD, BCPS. Created November 28, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.